Special Issue "SARS-CoV Spike Glycoprotein: Structure and Function"

A special issue of COVID (ISSN 2673-8112).

Deadline for manuscript submissions: 30 November 2021.

Special Issue Editors

Dr. Konstantinos Poulas
E-Mail Website
Guest Editor
Department of Pharmacy, University of Patras, 26500 Patras, Greece
Interests: immunology; structural biology; molecular biology; COVID-19; SARS-CoV-2 spike function; cholinergic pathway
Special Issues and Collections in MDPI journals
Dr. Konstantinos Farsalinos
grade E-Mail Website
Guest Editor
Dr. George Lagoumintzis
E-Mail Website
Guest Editor
Department of Pharmacy, University of Patras, Patras, Greece
Interests: immunology; structural biology; molecular biology; COVID-19; SARS-CoV-2 spike function; cholinergic pathway
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

The Spike Glycoprotein of Severe Acute Respiratory Coronaviruses plays a key role in the ACE-2 recognition and cell membrane fusion process. It is composed S1 and S2 subunits. The S1 subunit contains the Receptor Binding Domain (RBD) that recognizes and binds to the angiotensin-converting enzyme 2 (ACE-2). The S2 subunit mediates viral cell membrane fusion. The exact role of Spike Glycoprotein is under discussion. The same molecule is the main component of all the anti-COVID-19 vaccines and the anti-SPIKE neutralizing antibodies is an issue under extensive discussion. This Special Issue aims to publish original research (full length or short communications), review articles, opinions regarding but not limited to:

  • SARS-CoV and SARS-CoV-2 Spike Glycoprotein
  • Structure
  • Function
  • Interactions
  • Immunogenicity
  • Pathways
  • Vaccines
  • Targets

Dr. Konstantinos Poulas
Dr. Konstantinos Farsalinos
Dr. George Lagoumintzis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. COVID is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV
  • SARS-CoV-2
  • Spike Glycoprotein
  • Coronavirus
  • Receptor Binding Domain
  • anti-SPIKE antibodies

Published Papers

This special issue is now open for submission.
Back to TopTop